Metraipolis › archive › dc_73142e24290c
Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022 — Europe PMC PMID:41060960
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41060960
- DOI
- 10.1371/journal.pone.0332645
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T22:25:23.842Z
- SHA-256 of the archived text
9c05046b17329473d1f6effca38f33dba6d29ab495dcd018647f9f7268a72f16- Stable URL of this page
https://metraipolis.com/documento/dc_73142e24290c
How to cite
Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022 — Europe PMC PMID:41060960 — Europe PMC (en), https://europepmc.org/article/MED/41060960 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_73142e24290c (Metraipolis archive dc_73142e24290c, sha256 9c05046b17329473d1f6effca38f33dba6d29ab495dcd018647f9f7268a72f16)
BibTeX
@misc{dc73142e24290c,
title = {Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022 — Europe PMC PMID:41060960},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41060960},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_73142e24290c; sha256 9c05046b17329473d1f6effca38f33dba6d29ab495dcd018647f9f7268a72f16},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41060960. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Surveillance estimates of SARS-CoV-2 infections over time have relied on mandatory clinician and laboratory reporting. These estimates increasingly underestimated true viral incidence due to asymptomatic infections, variable access to testing, and self-administered diagnostics. To overcome these limitations, the North Carolina Department of Health and Human Services partnered with academic researchers to conduct three concurrent population-based longitudinal cohort studies in three distinct North Carolina counties to offer more accurate estimates of the incidence, prevalence, and vaccination rates for SARS-CoV-2. Methods: We enrolled and followed adult residents of three North Carolina counties from August 2020-February 2022. Demographic and health information was collected in biweekly surveys. Nasal swabs were collected biweekly and tested for SARS-CoV-2 using PCR testing. Blood samples were collected monthly and tested for antibodies to the SARS-CoV-2 nucleocapsid and spike proteins. We calculated monthly seroprevalence, sero-incidence, PCR test positivity, and vaccination uptake. Results: We enrolled 646 participants. Routine blood samples and nasal swab samples were contributed by 639 and 642 participants, respectively. By February 2022, 98% (95% CI: 97.4-98.2) had antibodies to the SARS-CoV-2 spike protein, and 13% (95% CI: 12.4-14.2) had antibodies to the nucleocapsid protein, indicating viral exposure. PCR testing detected infection among 14% (95% CI: 13.1-15.0) of participants, but cumulative PCR test positivity was only 1.3% (95% CI: 1.2-1.4). Over half of PCR-detected infections were asymptomatic. By February 2022, 97% of participants had completed the primary vaccine series, and 52% had received a booster dose. Conclusions: Nearly all participants had anti-SARS-CoV-2 antibodies by the end of follow-up, primarily through vaccination. The incidence of PCR-detected infections was similar to antibody testing, but PCR test positivity substantially underestimated incident infections. These findings emphasize the importance of prospective infection monitoring via antibody testing in a comprehensive approach to tracking viral infections in the community setting. Tema degli esploratori: scienze della vita e salute (ricerca Europe PMC «public health», solo open access). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-10-08). Identificativi: PMID 41060960 · PMCID PMC12507194 · DOI 10.1371/journal.pone.0332645. Descrittori MeSH principali: COVID-19; SARS-CoV-2. Pagina: https://europepmc.org/article/MED/41060960 — https://doi.org/10.1371/journal.pone.0332645. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T22:06:12.596Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.